{"id":52235,"date":"2025-12-30T13:52:24","date_gmt":"2025-12-30T05:52:24","guid":{"rendered":"https:\/\/flcube.com\/?p=52235"},"modified":"2025-12-30T13:52:25","modified_gmt":"2025-12-30T05:52:25","slug":"sino-biopharmaceuticals-tdi01-enrolls-first-ipf-patient-in-worlds-first-rock2-inhibitor-phase-iii-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52235","title":{"rendered":"Sino Biopharmaceutical&#8217;s TDI01 Enrolls First IPF Patient in World&#8217;s First ROCK2 Inhibitor Phase III Trial"},"content":{"rendered":"\n<p><strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced that <strong>TDI01<\/strong>, the world\u2019s first highly selective <strong>ROCK2 inhibitor<\/strong> to enter Phase\u202fIII trials for <strong>idiopathic pulmonary fibrosis (IPF)<\/strong>, has enrolled its <strong>first patient<\/strong>. Developed by subsidiary <strong>Beijing Tide Pharmaceutical<\/strong>, TDI01 targets the <strong>Angiocrine System<\/strong> to address vascular leakage, fibrosis, inflammation, and immune dysfunction simultaneously.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>TDI01 (ROCK2 inhibitor)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Beijing Tide Pharmaceutical (Sino Biopharm subsidiary)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Idiopathic pulmonary fibrosis (IPF)<\/td><\/tr><tr><td><strong>Study<\/strong><\/td><td>Phase\u202fIII pivotal trial<\/td><\/tr><tr><td><strong>Enrollment Status<\/strong><\/td><td>First patient enrolled (30\u202fDec\u202f2025)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Selective ROCK2 inhibition targeting Angiocrine System<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>World\u2019s first ROCK2 inhibitor<\/strong> in Phase\u202fIII for IPF<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: <strong>ROCK2<\/strong> (Rho\u2011associated coiled\u2011coil kinase\u202f2), a key regulator of the Angiocrine System<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: <strong>First\u2011in\u2011class<\/strong> selective ROCK2 inhibitor for IPF; avoids ROCK1\u2011related cardiovascular side effects<\/li>\n\n\n\n<li><strong>Multi\u2011dimensional Intervention<\/strong>:<\/li>\n\n\n\n<li><strong>Vascular leakage<\/strong>: Stabilizes endothelial barriers<\/li>\n\n\n\n<li><strong>Fibrosis<\/strong>: Inhibits myofibroblast activation and collagen deposition<\/li>\n\n\n\n<li><strong>Inflammation<\/strong>: Reduces pro\u2011inflammatory cytokine release<\/li>\n\n\n\n<li><strong>Immune dysfunction<\/strong>: Modulates macrophage polarization<\/li>\n\n\n\n<li><strong>Safety Window<\/strong>: Selective ROCK2 inhibition expands therapeutic index vs. non\u2011selective ROCK inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-design\">Clinical Trial Design<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Name<\/strong><\/td><td>TDI01\u2011IPF\u2011301 (Phase\u202fIII)<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Randomized, double\u2011blind, placebo\u2011controlled<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>~600 patients with progressive IPF<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Annual rate of decline in forced vital capacity (FVC)<\/td><\/tr><tr><td><strong>Key Secondary Endpoints<\/strong><\/td><td>Time to disease progression, mortality, safety<\/td><\/tr><tr><td><strong>Geography<\/strong><\/td><td>80 sites across China; potential global expansion<\/td><\/tr><tr><td><strong>Expected Completion<\/strong><\/td><td>Q4\u202f2027 (interim analysis Q2\u202f2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<p>China\u2019s <strong>IPF prevalence<\/strong> is estimated at <strong>180,000\u2011220,000 patients<\/strong>, with <strong>15,000\u201118,000 new cases annually<\/strong>. The domestic IPF therapeutics market reached <strong>\u00a52.8\u202fbillion<\/strong> in 2025, growing at a 12% CAGR.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>2025 China Sales (\u00a5)<\/th><th>Limitations<\/th><\/tr><\/thead><tbody><tr><td><strong>Pirfenidone<\/strong><\/td><td>Roche<\/td><td>Anti\u2011fibrotic (pyridone)<\/td><td>\u00a51.2\u202fbillion<\/td><td>Hepatotoxicity, photosensitivity<\/td><\/tr><tr><td><strong>Nintedanib<\/strong><\/td><td>Boehringer Ingelheim<\/td><td>Tyrosine kinase inhibitor<\/td><td>\u00a51.6\u202fbillion<\/td><td>Diarrhea, liver enzyme elevation<\/td><\/tr><tr><td><strong>TDI01<\/strong><\/td><td><strong>Sino Biopharma<\/strong><\/td><td><strong>ROCK2 inhibitor<\/strong><\/td><td>\u2013<\/td><td><strong>First disease\u2011modifying ROCK2 target<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Competitive Edge<\/strong>: TDI01\u2019s <strong>Angiocrine\u2011targeted mechanism<\/strong> addresses <strong>four pathological drivers<\/strong> simultaneously, potentially offering <strong>superior efficacy<\/strong> and <strong>better tolerability<\/strong> vs. existing anti\u2011fibrotics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections-amp-development-timeline\">Financial Projections &amp; Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Target Date<\/th><th>Financial Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202fIII interim data<\/strong><\/td><td>Q2\u202f2026<\/td><td>Supports BTD application<\/td><\/tr><tr><td><strong>NMPA submission<\/strong><\/td><td>Q1\u202f2028<\/td><td>Accelerated review pathway<\/td><\/tr><tr><td><strong>Potential approval<\/strong><\/td><td>Q4\u202f2028<\/td><td>First\u2011in\u2011class launch<\/td><\/tr><tr><td><strong>Peak penetration (2032E)<\/strong><\/td><td>25% of IPF patients<\/td><td><strong>\u00a52.1\u202fbillion<\/strong> (US$295\u202fmillion)<\/td><\/tr><tr><td><strong>Royalty to Tide Pharma<\/strong><\/td><td>\u2013<\/td><td>15% of net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Investment<\/strong>: Sino Biopharma has allocated <strong>\u00a5450\u202fmillion<\/strong> to the TDI01 program through 2028, including <strong>\u00a5180\u202fmillion<\/strong> for Phase\u202fIII trials.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding TDI01\u2019s clinical development, regulatory timeline, market potential, and competitive positioning. Actual results may differ materially due to clinical trial outcomes, competitive responses, and NMPA regulatory decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG: 1177) announced that TDI01, the world\u2019s first highly selective ROCK2 inhibitor&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52236,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,908,24,313],"class_list":["post-52235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-1177","tag-rare-orphan-disease-drugs","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical&#039;s TDI01 Enrolls First IPF Patient in World&#039;s First ROCK2 Inhibitor Phase III Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TDI01, the world\u2019s first highly selective ROCK2 inhibitor to enter Phase\u202fIII trials for idiopathic pulmonary fibrosis (IPF), has enrolled its first patient. Developed by subsidiary Beijing Tide Pharmaceutical, TDI01 targets the Angiocrine System to address vascular leakage, fibrosis, inflammation, and immune dysfunction simultaneously.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52235\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical&#039;s TDI01 Enrolls First IPF Patient in World&#039;s First ROCK2 Inhibitor Phase III Trial\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TDI01, the world\u2019s first highly selective ROCK2 inhibitor to enter Phase\u202fIII trials for idiopathic pulmonary fibrosis (IPF), has enrolled its first patient. Developed by subsidiary Beijing Tide Pharmaceutical, TDI01 targets the Angiocrine System to address vascular leakage, fibrosis, inflammation, and immune dysfunction simultaneously.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52235\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-30T05:52:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-30T05:52:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52235#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52235\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical&#8217;s TDI01 Enrolls First IPF Patient in World&#8217;s First ROCK2 Inhibitor Phase III Trial\",\"datePublished\":\"2025-12-30T05:52:24+00:00\",\"dateModified\":\"2025-12-30T05:52:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52235\"},\"wordCount\":438,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52235#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3002.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 1177\",\"Rare \\\/ orphan disease drugs\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52235#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52235\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52235\",\"name\":\"Sino Biopharmaceutical's TDI01 Enrolls First IPF Patient in World's First ROCK2 Inhibitor Phase III Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52235#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52235#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3002.webp\",\"datePublished\":\"2025-12-30T05:52:24+00:00\",\"dateModified\":\"2025-12-30T05:52:25+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TDI01, the world\u2019s first highly selective ROCK2 inhibitor to enter Phase\u202fIII trials for idiopathic pulmonary fibrosis (IPF), has enrolled its first patient. Developed by subsidiary Beijing Tide Pharmaceutical, TDI01 targets the Angiocrine System to address vascular leakage, fibrosis, inflammation, and immune dysfunction simultaneously.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52235#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52235\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52235#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharmaceutical's TDI01 Enrolls First IPF Patient in World's First ROCK2 Inhibitor Phase III Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52235#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical&#8217;s TDI01 Enrolls First IPF Patient in World&#8217;s First ROCK2 Inhibitor Phase III Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical's TDI01 Enrolls First IPF Patient in World's First ROCK2 Inhibitor Phase III Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TDI01, the world\u2019s first highly selective ROCK2 inhibitor to enter Phase\u202fIII trials for idiopathic pulmonary fibrosis (IPF), has enrolled its first patient. Developed by subsidiary Beijing Tide Pharmaceutical, TDI01 targets the Angiocrine System to address vascular leakage, fibrosis, inflammation, and immune dysfunction simultaneously.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52235","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical's TDI01 Enrolls First IPF Patient in World's First ROCK2 Inhibitor Phase III Trial","og_description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TDI01, the world\u2019s first highly selective ROCK2 inhibitor to enter Phase\u202fIII trials for idiopathic pulmonary fibrosis (IPF), has enrolled its first patient. Developed by subsidiary Beijing Tide Pharmaceutical, TDI01 targets the Angiocrine System to address vascular leakage, fibrosis, inflammation, and immune dysfunction simultaneously.","og_url":"https:\/\/flcube.com\/?p=52235","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-30T05:52:24+00:00","article_modified_time":"2025-12-30T05:52:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52235#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52235"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical&#8217;s TDI01 Enrolls First IPF Patient in World&#8217;s First ROCK2 Inhibitor Phase III Trial","datePublished":"2025-12-30T05:52:24+00:00","dateModified":"2025-12-30T05:52:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52235"},"wordCount":438,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52235#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3002.webp","keywords":["Clinical trial approval \/ initiation","HKG: 1177","Rare \/ orphan disease drugs","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52235#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52235","url":"https:\/\/flcube.com\/?p=52235","name":"Sino Biopharmaceutical's TDI01 Enrolls First IPF Patient in World's First ROCK2 Inhibitor Phase III Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52235#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52235#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3002.webp","datePublished":"2025-12-30T05:52:24+00:00","dateModified":"2025-12-30T05:52:25+00:00","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TDI01, the world\u2019s first highly selective ROCK2 inhibitor to enter Phase\u202fIII trials for idiopathic pulmonary fibrosis (IPF), has enrolled its first patient. Developed by subsidiary Beijing Tide Pharmaceutical, TDI01 targets the Angiocrine System to address vascular leakage, fibrosis, inflammation, and immune dysfunction simultaneously.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52235#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52235"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52235#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3002.webp","width":1080,"height":608,"caption":"Sino Biopharmaceutical's TDI01 Enrolls First IPF Patient in World's First ROCK2 Inhibitor Phase III Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52235#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical&#8217;s TDI01 Enrolls First IPF Patient in World&#8217;s First ROCK2 Inhibitor Phase III Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52235"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52235\/revisions"}],"predecessor-version":[{"id":52237,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52235\/revisions\/52237"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52236"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}